Y-mAbs Omblastys gets FDA priority review to treat children with nerve cell cancer

May 31, 2022 9:46 AM ETY-mAbs Therapeutics, Inc. (YMAB)By: Ravikash, SA News Editor

Headquarters of US Food and Drug Administration (FDA)

Grandbrothers/iStock Editorial via Getty Images

  • The U.S. Food and Drug Administration granted priority review to Y-mAbs Therapeutics's (NASDAQ:YMAB) application seeking approval of Omblastys (omburtamab) to treat children with CNS/leptomeningeal metastasis from neuroblastoma.
  • The FDA is expected to make a decision on the biologics license application by Nov. 30. Under priority review the FDA intends to take action on an application within six months, compared to 10 months under standard review.
  • The company said that the FDA is planning to hold an advisory committee meeting in October to discuss the application.
  • Neuroblastoma is a disease in which cancer cells form in neuroblasts (immature nerve tissue) in the adrenal glands, neck, chest or spinal cord. Leptomeningeal metastases occur when cancer spreads to the membranes lining the brain and spinal cord.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.